News stories about Bellicum Pharmaceuticals (NASDAQ:BLCM) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bellicum Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.0953642401258 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several research firms have recently issued reports on BLCM. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Raymond James Financial reaffirmed a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. Zacks Investment Research cut Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price objective (down from $12.00) on shares of Bellicum Pharmaceuticals in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. Bellicum Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $16.88.
Shares of Bellicum Pharmaceuticals stock traded down $0.27 on Friday, hitting $6.39. The stock had a trading volume of 312,031 shares, compared to its average volume of 561,094. Bellicum Pharmaceuticals has a 52-week low of $5.02 and a 52-week high of $14.49. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.37 and a current ratio of 8.37. The company has a market capitalization of $214.53, a P/E ratio of -2.25 and a beta of 0.47.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.08. The firm had revenue of ($0.07) million during the quarter, compared to analysts’ expectations of $0.08 million. analysts forecast that Bellicum Pharmaceuticals will post -2.67 earnings per share for the current year.
In other news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total value of $2,248,978.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 1,141,822 shares of company stock valued at $9,475,583 over the last three months. Company insiders own 18.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/bellicum-pharmaceuticals-blcm-earning-somewhat-favorable-press-coverage-analysis-finds.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.